MCF Advisors’s Opus Genetics IRD Stock Holding History

MCF Advisors’s Portfolio IRD Stock Details IRD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-10,565	Closed	-$20K	–	880
2022 Q2	$20K	Buy	10,565 +1,066	+11%	+$2.42K	﹤0.01%	445
2022 Q1	$31K	Buy	+9,499	New	+$32.5K	﹤0.01%	403
2021 Q4	–	Sell	-9,499	Closed	-$49K	–	719
2021 Q3	$49K	Hold	9,499	–	–	0.01%	308
2021 Q2	$50K	Hold	9,499	–	–	0.01%	284
2021 Q1	$55K	Buy	+9,499	New	+$88.3K	0.01%	261

Other funds holding IRD

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

RHJA

Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return

MCM

MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return

Richmond Brothers Jackson, Michigan $150M AUM 14.02% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Comerica Bank Dallas, Texas $25.1B AUM 24.68% 1-Year Est. Return

MCF Advisors's IRD Position: Q3 2022 in Review

MCF Advisors sold out of Opus Genetics (IRD) in Q3 2022, closing a stake of 10,565 shares — an estimated $20K sold.

MCF Advisors first reported a position in IRD in Q1 2021 and held it in 5 quarters. The position peaked at $55K in Q1 2021. 37 funds tracked by Wall St. Rank hold IRD as of Q3 2022.

MCF Advisors reported no remaining Opus Genetics position as of Q3 2022 after selling out during the quarter.
MCF Advisors sold 10,565 Opus Genetics shares in Q3 2022, an estimated $20K.
MCF Advisors first reported a position in Opus Genetics in Q1 2021 and held it in 5 quarters.
MCF Advisors's Opus Genetics position peaked at $55K in Q1 2021.
37 funds tracked by Wall St. Rank held Opus Genetics as of Q3 2022.

Based on MCF Advisors's 13F filing for Q3 2022, filed 9 Nov 2022.